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Pathologically confirmed breast cancer in Malawi: a 
descriptive study: Clinical profile of breast cancer
                         Abstract
Background 
Breast cancer is the most common female cancer in Africa, yet no published 
studies have investigated breast cancer in Malawi. Understanding the 
clinical profile of  breast cancer is important to develop early diagnosis 
efforts.
Aim
To describe clinical and pathological characteristics of  breast specimens 
from a pathology laboratory at a national teaching hospital. 
Methods
Secondary analysis of  pathology reports from July 2011 to September 
2013.
Results 
Among 85 breast cancer cases, 55% were < 50 years. Median tumor size 
was 4 cm and 49% were grade 3. Median symptom duration was eight 
months. 
Conclusions 
Malawian women with breast cancer commonly have long symptom 
durations prior to diagnosis, young age, and poorly differentiated tumors. 
Improved clinical and pathological characterization, including hormone 
receptor status, are urgently needed to better understand this disease in 
Malawi.
Introduction 
Breast cancer is the most common cancer and the leading 
cause of  cancer death in Africa1. The  breast cancer 
burden has increased across the continent with significant 
geographic and socioeconomic variation2. Low cancer 
awareness and lack of  screening or control programs lead to 
many women being diagnosed late3. Although most breast 
cancer studies in Africa are small, retrospective descriptions 
with limited follow-up, available data suggest that African 
women are frequently diagnosed with advanced disease and 
have poor clinical outcomes. Some studies in African settings 
have shown high frequencies of  aggressive tumour types 
with poorly differentiated tumours that are often hormone 
receptor (HR) negative. However, HR status assessment is not 
routinely done in many countries including Malawi4-6. This is 
partly due to an extreme scarcity of  diagnostic pathology 
services in Africa7. In Malawi’s Central Region, pathology 
diagnostic services were bolstered by the establishment, in 
July 2011, of  a diagnostic pathology laboratory at Kamuzu 
Central Hospital (KCH), a teaching hospital in Lilongwe8. 
At KCH, efforts are ongoing to routinely assess HR status 
for all confirmed breast cancers, leveraging clinical research 
collaborations which provide immunohistochemistry 
reagents and technical support for new staining procedures8. 
This institutional database provides important data for 
understanding breast cancer in the Malawian context. 
Breast cancer accounts for 8% of  female cancers in Malawi9,10. 
In a previous report from a histopathology laboratory in 
the Southern Region of  the country, breast biopsies were 
the second most common type of  biopsies sent to the 
laboratory, after esophageal specimens11. Understanding the 
clinical spectrum of  breast cancer in Malawi is important 
to develop early diagnosis efforts to address high mortality 
rates. This cross-sectional study aimed to describe the 
pathological characteristics of  breast specimens submitted 
to the KCH Pathology Laboratory, along with the clinical 
features corresponding to these specimens. 
Methods
We reviewed KCH pathology reports from July 2011 to 
September 2013. KCH is a tertiary referral hospital for 
the Central Region of  Malawi and the only hospital with 
pathology services in this region. Suspected breast cancer 
may be diagnosed after a core biopsy, fine needle aspiration 
(FNA), excisional or incisional biopsy, or surgical specimen. 
The KCH pathology database includes information on age, 
sex, HIV status, nature of  the specimen, date of  collection, 
date of  receipt, date of  report, clinical notes, macroscopy, 
microscopy, and diagnostic conclusion. For confirmed breast 
cancers, we abstracted data on tumor size, grade, lymph node 
involvement, and symptoms when available. HR status was 
not routinely available during this period and clinical data 
from patient charts were unavailable for review. To minimize 
errors during data abstraction, two co-authors independently 
reviewed reports of  all specimens and discussed discrepant 
results to reach consensus. We excluded specimens from 
men and inadequate or non-representative specimens. 
We used descriptive statistics to report proportions and 
frequencies assessed, and used Pearson’s Chi-square and 
t-tests to determine statistical significance. All analyses were 
performed using Stata version 12. This study was reviewed by 
the Malawian National Health Sciences Review Committee 
and exempted of  patient informed consent due to the nature 
of  secondary analyses of  routinely collected data; it was also 
approved by the University of  North Carolina institutional 
review board. 
Results
There were 238 breast specimens in the pathology database 
during the 26-month study period. Eleven specimens from 
men (five were cancer) and 12 non-diagnostic specimens were 
excluded. We included one specimen per woman using the 
largest submitted specimen as the definitive report, leaving 
193 women as shown in Table 1.  The age range of  patients 
was 12-89 with a median of  34 years. Fifty-five percent (106) 
of  the reports had a non-cancer diagnosis; two women were 
diagnosed with lymphoma. Fibroadenoma made up 87% of  
the benign breast diagnoses. Women without cancer were 
younger than those with cancer (median age 24 vs 46 years, 
p < 0.001).Characteristics of  the 85 confirmed breast cancer 
cases are displayed in Table 2. Fifty-five percent of  cases 
occurred in women < 50 years old. Invasive ductal carcinoma 
was the most common histologic type (86%). Histologic 
grade was available for 53 cases and 49% were grade 3. Of  
42 specimens with lymph nodes submitted to the lab, 83% 
had involvement by cancer. Among women with invasive 
cancer, two had Paget’s disease and four women had ductal 
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carcinoma in situ. Clinical notes were available for 44 women. 
Although the notes indicated a palpable breast mass as the 
only symptom for 13 cases, many others included multiple 
symptoms.  Commonly reported symptoms included fixed 
or mobile axillary lymphadenopathy (17), ulcerated lesion or 
mass (9), breast enlargement/swelling (5), peau d’orange (3), 
breast pain (3), multiple breast masses (2), nipple discharge 
(2), and nipple retraction (2). Of  these, 30 had notes on 
symptom duration; the median reported length was 8 
months (range 2-24 months) and 47% had symptoms for 
> 12 months. Median tumor size was 4 cm (range 1-10 cm) 
and 45% were ≥ 5 cm. TNM stage could not be assigned 
retrospectively for most confirmed cases using available data.
Table 1. Descriptive summary of breast biopsy reports at Kamuzu 
Central Hospital in Lilongwe, Malawi
Table 2. Clinical characteristics of confirmed breast cancer cases at 
Kamuzu Central Hospital in Lilongwe, Malawi
Discussion
Malawian women with breast cancer have long symptom 
durations prior to diagnosis, a majority have poorly 
differentiated tumors of  ductal origin, and they are commonly 
diagnosed at young ages. These findings are consistent 
with other studies in the region where many patients are 
diagnosed with advanced disease and aggressive clinical 
features. Nearly half  of  cases had high-grade tumours and 
over 80% of  those with available lymph node information 
had lymph node involvement. One potential explanation for 
this may be that women with more aggressive tumours seek 
care and receive diagnostic services compared to women 
with slower progressing tumours4. A majority of  cases 
occurred in women under 50 years of  age, and the mean 
age was 48.6 years. This is similar to findings from Blantyre, 
where the mean age of  19 cases from the Southern Region 
of  Malawi was 50.7 years11. It remains uncertain whether 
younger age at breast cancer diagnosis in African settings 
reflects environmental factors, genetic factors, differences 
in tumor biology, or the younger demographic profile of  
African countries overall. To our knowledge this is the first 
to attempt describe clinical features of  breast cancer in 
Malawi, therefore this study provides essential baseline data 
regarding tumor biology and clinical presentations in our 
setting. We were unable to determine stage for most of  the 
cancer cases due to limitations of  available clinical records. 
We were unable to obtain detailed data regarding treatment 
and outcomes because patient charts were not accessible. 
However, these findings provide important insight into the 
local presentation of  breast cancer. In particular, the absence 
of  HR status testing in most African settings is a major 
deficiency in care that requires correction, not only in Malawi 
but throughout the region. HR positivity varies widely across 
Africa,4,12,13 and routine testing would ensure that women 
with HR-negative cancers are spared ineffective hormonal 
therapy. It would also identify many women who would 
benefit from tamoxifen, which is relatively inexpensive, 
well-tolerated, and available in Malawi. Detailed prospective 
studies of  breast cancer in Malawi are urgently needed.  
Conclusions
Aggressive breast cancer affects many young and middle-
aged Malawian women. There is a need for more expedient 
evaluation of  breast masses to enable earlier diagnosis 
and treatment. Increasing breast cancer awareness is also 
imperative to address late diagnosis. Improved clinical 
and pathological characterization, including HR status, are 
needed to better understand this disease in our setting and 
improve outcomes. Such efforts are currently ongoing across 
Malawi and will hopefully lead to more detailed breast cancer 
data from Malawi moving forward.
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